Resmed (RSMDF) EPS (Weighted Average and Diluted) (2009 - 2026)

Resmed has reported EPS (Weighted Average and Diluted) for 18 years, with the latest figure at $2.74 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 10.48% year-over-year to $2.74; the trailing twelve-month figure through Mar 2026 stood at $10.37 (up 16.39% YoY), and the FY2025 full-year result was $9.51, up 37.43% from the prior year.
• EPS (Weighted Average and Diluted) for Q1 2026 stood at $2.74, up from $2.68 in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was $2.74 in Q1 2026, with the low at $1.22 in Q1 2022.
• Historically, EPS (Weighted Average and Diluted) has averaged $1.93 across 5 years, with a median of $1.98 in 2024.
• Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) soared 325.93% — and 2023, when it dropped 7.19%.
• Resmed's EPS (Weighted Average and Diluted) stood at $1.53 in 2022, then dropped by 7.19% to $1.42 in 2023, then jumped by 64.79% to $2.34 in 2024, then increased by 14.53% to $2.68 in 2025, then advanced by 2.24% to $2.74 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $2.74 (Q1 2026), $2.68 (Q4 2025), and $2.37 (Q3 2025), per Business Quant data.